Cardiotoxicity in Children With Acute Ieukemia Treated by Anthracycline; Detected by Cardiac Troponins and Echcocardiography

Yaran Abbas  Abdulqader; Mouroge Hashim  Al-Ani; Nadine Abdulrazzak  Mahmood

doi:10.56056/amj.2018.61

Authors

Yaran Abbas Abdulqader M. B. Ch. B, Board candidate of pediatrics
Mouroge Hashim Al-Ani M. B. Ch. B/ C.A.B.P. Professor of pediatrics, at Hawler Medical University
Nadine Abdulrazzak Mahmood M. B. Ch. B/C.A.B.P/D.Ch (Pediatric cardiology), Hawler Medical University

DOI:

https://doi.org/10.56056/amj.2018.61

Keywords:

Acute Leukemia, Cardiac Troponins, Cardiotoxicity

Abstract

Background and objectives:the use of anthracycline antineoplastic agents has conducted to improved pediatric malignancies’ outcomes, yet their use is limited by their potential cardiotoxic effects. Thus, children who have received anthracyclines require cardiac evaluation periodically. The serum levels of cardiac troponins have been shown to be elevated in response to severity of cardiac dysfunction. The aim of our study was to investigate the role of serum levels of cardiac troponin and echocardiography as sensitive markers for anthracycline-induced cardiotoxicity in children with malignancy.

Methods:we carried out this study at Nanakali Hospital, Pediatric Hematology and Oncology unit. We measured plasma high sensitive cardiac troponin T in 24 patients who received anthracyclines for their malignancy at cumulative doses of 75-310mg/m2, between Feb 2017 and Feb 2018. Evaluation of the patients for cardiac functions included physical examination, chest X-ray and echocardiography in addition to cardiac troponins.

Results: Of the 24 patients, 3 (12.5%) had abnormal cardiac functions by echocardiography. Serum troponin level in two of them was significantly elevated. Physical findings of the patients were significant. Chest X-ray in 2 (8.3%) showed radiological findings.

Conclusions: Serum troponin concentration and Echocardiography may be practical and sensitive indicator of abnormal cardiac function in children receiving anthracycline therapy.

Downloads

Download data is not yet available.

References

Hinkle A, Proukou C, French C et al, A clinic-based, comprehensive care model for studying late effects in long-term survivors of pediatric illnesses. .Pediatrics 2004; 113(Suppl.4),1141–5.

Reulen R, Winter D, Frobisher C et al. Long-term cause-specific mortality among survivors of childhood cancer. JAMA 2010;304(2),172– 9.

Arola O., Saraste A, Pulkki K et al. Acute doxorubicin cardiotoxicity involves cardiomyocyte apoptosis. Cancer Research. 2000; 60(7):1789–92.

Zordoky B, Mohamed A, Aboutabl M. et al, “Acute doxorubicin cardiotoxicity alters cardiac cytochrome P450 expression and arachidonic acid metabolism in rats.. Drug Metabolism and Disposition August .2011.39 (8) 1440-50

Cheitlin M, Armstrong W, Aurigemma G et al.: ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography: summary article: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (ACC/ AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography). Circulation.2003;108: 1146-62.

Landier W, Bhatia S, Eshelman D, et al. Development of risk-based guidelines for pediatric cancer survivors: the Children’s Oncology Group Long Term Follow-Up Guidelines from the Children’s Oncology Group Late Effects Committee and Nursing Discipline. J Clin Oncol 2004; 15:4979-90.

Lipshultz S. Ventricular dysfunction clinical research in infants, children and adolescents. Prog Pediatr Cardiol 2000; 12:1-28.

Lipshultz S, Rifai N, Sallan S, et al. Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury. Circulation. 1997; 96:2641-8.

Lipshultz S, Somers M, Lipsitz S et al. Serum cardiac troponin and subclinical cardiac status in pediatric chronic renal failure. Pediatrics 2003;112: 79-86.

Herman E, Lipshultz S, Ferrans V. The use of cardiac biomarkers to detect myocardialdamage induced by chemotherapeutic agents. In: Wu AHB, ed. Cardiac markers. 2nd ed. Totowa, N.J.: Humana Press. 2003: 87-109

Lipshultz S, Giantris A, Lipsitz S, et al. the Dana-Farber 91-01 Acute Lymphoblastic Leukemia protocol. J Clin Oncol 2002; 20:1677-82.

Outomuro D, Grana DR, Azzato F et al. Adriamycin-induced myocardial toxicity: new solutions for an old problem? Int. J. Cardiol. 2007:117(1), 6–15.

Mordente A, Meucci E, Martorana G et al. Human heart cytosolic reductases and anthracycline cardiotoxicity. IUBMB Life 2001:52, 83– 88.

Barry E, Alvarez J, Scully R et al. Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management. Expert Opin Pharmacother. 2007; 8:1039–58.

Wouters K, Kremer L, Miller T et al. Protecting against anthracycline- induced myocardial damage: a review of the most promising strategies. Br J Haematol. 2005; 131:561–7